Glycofren (Metformin Hydrochloride)

Glycofren is indicated for the management of elevated blood glucose levels associated with type 2 diabetes mellitus, and may be used as part of a comprehensive treatment plan that includes diet, exercise, and other glucose‑lowering agents.

• Adjunct therapy when diet and exercise alone do not achieve target glycemic control.
• Combination with other oral antidiabetic agents such as sulfonylureas or DPP‑4 inhibitors.
• Use in patients with mild to moderate renal impairment under clinical supervision.
• Off‑label consideration for polycystic ovary syndrome when prescribed by a specialist.
• May be prescribed in elderly patients after dose adjustment.

Like other metformin products, Glycofren can cause a range of side effects that vary in frequency and severity.

Common

• Nausea, vomiting, or loss of appetite.
• Diarrhea or abdominal cramping.
• Metallic taste in the mouth.
• Weight loss or decreased appetite.

Serious

• Lactic acidosis, a rare but life‑threatening metabolic condition.
• Severe skin reactions such as Stevens‑Johnson syndrome.
• Marked hypoglycemia when combined with insulin or secretagogues.
• Persistent gastrointestinal distress leading to dehydration.

Before starting Glycofren, healthcare providers assess several clinical factors to minimize risks and ensure safe use.

• Assess renal function; contraindicated in severe renal impairment.
• Monitor liver enzymes periodically during therapy.
• Evaluate for signs of heart failure or hypoxia.
• Use caution in patients with a history of alcohol abuse.
• Pregnancy and breastfeeding status should be reviewed; safety data are limited.
• Adjust dose in elderly patients due to altered pharmacokinetics.
• Regularly check vitamin B12 levels during long‑term treatment.

Glycofren may interact with other medicines, affecting blood glucose levels or increasing the risk of adverse events.

Avoid

• Concurrent use with iodinated contrast agents without adequate hydration.
• Combination with other biguanides or high‑dose metformin formulations.
• Co‑administration with potent CYP450 inhibitors that affect renal clearance.

Use with caution

• Sulfonylureas, meglitinides, or insulin, which may increase hypoglycemia risk.
• Corticosteroids, thiazide diuretics, or beta‑blockers that can raise glucose levels.
• Alcohol consumption, which may predispose to lactic acidosis.
• Radiographic contrast studies; ensure proper hydration and monitoring.